Brighton Jones LLC Sells 250 Shares of Amgen Inc. (NASDAQ:AMGN)

Brighton Jones LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 1.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,778 shares of the medical research company’s stock after selling 250 shares during the quarter. Brighton Jones LLC’s holdings in Amgen were worth $7,430,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Strategic Financial Concepts LLC bought a new stake in shares of Amgen in the 2nd quarter worth approximately $26,000. Horizon Financial Services LLC bought a new position in Amgen in the 1st quarter valued at approximately $28,000. United Community Bank bought a new position in Amgen in the 4th quarter valued at approximately $29,000. nVerses Capital LLC bought a new position in Amgen in the 2nd quarter valued at approximately $31,000. Finally, Bbjs Financial Advisors LLC bought a new position in Amgen in the 2nd quarter valued at approximately $33,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Up 0.9 %

NASDAQ:AMGN opened at $335.95 on Friday. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The firm has a market capitalization of $180.22 billion, a price-to-earnings ratio of 47.99, a price-to-earnings-growth ratio of 2.93 and a beta of 0.61. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85. The business has a fifty day moving average price of $329.44 and a 200-day moving average price of $305.22.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter in the previous year, the company posted $5.00 EPS. The company’s quarterly revenue was up 20.1% on a year-over-year basis. Sell-side analysts forecast that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.68%. Amgen’s payout ratio is presently 128.57%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price objective (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Royal Bank of Canada upped their price objective on Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. TD Cowen upped their price objective on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Argus increased their price target on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Eleven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus price target of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.